Cardiol Therapeutics (CRDL) Stock Analysis

What Cardiol Therapeutics does

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.

Key metrics

ETFs linked to CRDL

Broad-market and Healthcare sector ETFs an investor holding Cardiol Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CRDL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cardiol Therapeutics?

Cardiol Therapeutics trades under the ticker CRDL on NASDAQ.

Which exchange is CRDL listed on?

CRDL is listed on NASDAQ.

What sector does Cardiol Therapeutics operate in?

Cardiol Therapeutics is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze CRDL in a portfolio?

PortView shows CRDL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.